Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review

BackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient. This meta-analysis aimed to evaluate the efficacy and...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Wang, Wenmin Yang, Yuan Yang, Xingning Liu, Lanfen Peng, Qi Huang, Kongli Fan, Rui Hu, Jinyu Yi, Xin Zhong, Jing Li, Jialing Sun, Xiaozhou Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1516204/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832542399969099776
author Yan Wang
Yan Wang
Wenmin Yang
Wenmin Yang
Yuan Yang
Yuan Yang
Xingning Liu
Xingning Liu
Lanfen Peng
Lanfen Peng
Qi Huang
Qi Huang
Qi Huang
Kongli Fan
Kongli Fan
Rui Hu
Rui Hu
Jinyu Yi
Jinyu Yi
Xin Zhong
Xin Zhong
Jing Li
Jialing Sun
Xiaozhou Zhou
Xiaozhou Zhou
author_facet Yan Wang
Yan Wang
Wenmin Yang
Wenmin Yang
Yuan Yang
Yuan Yang
Xingning Liu
Xingning Liu
Lanfen Peng
Lanfen Peng
Qi Huang
Qi Huang
Qi Huang
Kongli Fan
Kongli Fan
Rui Hu
Rui Hu
Jinyu Yi
Jinyu Yi
Xin Zhong
Xin Zhong
Jing Li
Jialing Sun
Xiaozhou Zhou
Xiaozhou Zhou
author_sort Yan Wang
collection DOAJ
description BackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient. This meta-analysis aimed to evaluate the efficacy and safety of Silibinin capsules in the treatment of ALD.MethodsThe study was registered with PROSPERO (CRD42024509676). Randomized controlled trials (RCTs) were included from six databases, covering the period from database inception to 30 December 2023. Primary outcomes included liver function indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), lipid indicators including triglycerides (TG) and total cholesterol (TC), coagulation indicators including prothrombin time (PT), liver fibrosis indicator (PC-III), and Effective Rate. Analysis was performed using Review Manager 5.4.1 and STATA 14.0.ResultsIn 15 RCTs involving 1,221 patients, compared to the non-Silibinin group, Silibinin capsules showed significant efficacy in terms of liver function, lipid levels, and effective rate in patients with ALD. Detailed parameters were as follows: ALT [SMD = −1.16, 95% CI (−1.84, −0.47)], AST [SMD = −1.56, 95% CI (−2.18, −0.95)], GGT [SMD = −1.48, 95% CI (−2.09, −0.87)], TBIL [SMD = −1.14, 95% CI (−2.16, −0.13)], TG [SMD = −1.29, 95% CI (−1.93, −0.66)], TC [SMD = −1.11, 95% CI (−1.61, −0.61)], PT [SMD = −0.01, 95% CI (−0.29, 0.26)], PC-III [SMD = −1.94, 95% CI (−3.04, −0.84)], and Effective Rate [OR = 3.60, 95% CI (2.28, 5.70)]. Importantly, Silibinin capsules exhibited a favorable safety profile, with only mild gastrointestinal reactions and reports of insomnia as adverse events.ConclusionThis review reveals the clinical efficacy and safety of Silibinin capsules in the treatment of ALD, and confirms that the drug is an effective adjuvant therapy to alleviate ALD. At present, the mechanism of action of this drug for ALD is still unclear, and we expect more experimental studies to prove the clinical value of Silibinin capsules.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=509676.
format Article
id doaj-art-bdbf8857f53f4a08a19c76326aa9843e
institution Kabale University
issn 1663-9812
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-bdbf8857f53f4a08a19c76326aa9843e2025-02-04T05:28:04ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-02-011610.3389/fphar.2025.15162041516204Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic reviewYan Wang0Yan Wang1Wenmin Yang2Wenmin Yang3Yuan Yang4Yuan Yang5Xingning Liu6Xingning Liu7Lanfen Peng8Lanfen Peng9Qi Huang10Qi Huang11Qi Huang12Kongli Fan13Kongli Fan14Rui Hu15Rui Hu16Jinyu Yi17Jinyu Yi18Xin Zhong19Xin Zhong20Jing Li21Jialing Sun22Xiaozhou Zhou23Xiaozhou Zhou24Department of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaFaculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaFaculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaFaculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaDepartment of Liver Disease, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, ChinaDepartment of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, ChinaBackgroundIn recent years, the incidence of alcoholic liver disease (ALD) has rapidly increased worldwide, becoming a significant health issue. Silibinin capsules have shown potential in treating ALD, but clinical evidence is still insufficient. This meta-analysis aimed to evaluate the efficacy and safety of Silibinin capsules in the treatment of ALD.MethodsThe study was registered with PROSPERO (CRD42024509676). Randomized controlled trials (RCTs) were included from six databases, covering the period from database inception to 30 December 2023. Primary outcomes included liver function indicators such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), lipid indicators including triglycerides (TG) and total cholesterol (TC), coagulation indicators including prothrombin time (PT), liver fibrosis indicator (PC-III), and Effective Rate. Analysis was performed using Review Manager 5.4.1 and STATA 14.0.ResultsIn 15 RCTs involving 1,221 patients, compared to the non-Silibinin group, Silibinin capsules showed significant efficacy in terms of liver function, lipid levels, and effective rate in patients with ALD. Detailed parameters were as follows: ALT [SMD = −1.16, 95% CI (−1.84, −0.47)], AST [SMD = −1.56, 95% CI (−2.18, −0.95)], GGT [SMD = −1.48, 95% CI (−2.09, −0.87)], TBIL [SMD = −1.14, 95% CI (−2.16, −0.13)], TG [SMD = −1.29, 95% CI (−1.93, −0.66)], TC [SMD = −1.11, 95% CI (−1.61, −0.61)], PT [SMD = −0.01, 95% CI (−0.29, 0.26)], PC-III [SMD = −1.94, 95% CI (−3.04, −0.84)], and Effective Rate [OR = 3.60, 95% CI (2.28, 5.70)]. Importantly, Silibinin capsules exhibited a favorable safety profile, with only mild gastrointestinal reactions and reports of insomnia as adverse events.ConclusionThis review reveals the clinical efficacy and safety of Silibinin capsules in the treatment of ALD, and confirms that the drug is an effective adjuvant therapy to alleviate ALD. At present, the mechanism of action of this drug for ALD is still unclear, and we expect more experimental studies to prove the clinical value of Silibinin capsules.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=509676.https://www.frontiersin.org/articles/10.3389/fphar.2025.1516204/fullSilibinin capsulesALDrctmeta-analysissystematic reviewChinese patent
spellingShingle Yan Wang
Yan Wang
Wenmin Yang
Wenmin Yang
Yuan Yang
Yuan Yang
Xingning Liu
Xingning Liu
Lanfen Peng
Lanfen Peng
Qi Huang
Qi Huang
Qi Huang
Kongli Fan
Kongli Fan
Rui Hu
Rui Hu
Jinyu Yi
Jinyu Yi
Xin Zhong
Xin Zhong
Jing Li
Jialing Sun
Xiaozhou Zhou
Xiaozhou Zhou
Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
Frontiers in Pharmacology
Silibinin capsules
ALD
rct
meta-analysis
systematic review
Chinese patent
title Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
title_full Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
title_fullStr Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
title_full_unstemmed Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
title_short Evidence construction of Silibinin capsules against alcoholic liver disease based on a meta-analysis and systematic review
title_sort evidence construction of silibinin capsules against alcoholic liver disease based on a meta analysis and systematic review
topic Silibinin capsules
ALD
rct
meta-analysis
systematic review
Chinese patent
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1516204/full
work_keys_str_mv AT yanwang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT yanwang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT wenminyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT wenminyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT yuanyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT yuanyang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT xingningliu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT xingningliu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT lanfenpeng evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT lanfenpeng evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT qihuang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT qihuang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT qihuang evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT konglifan evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT konglifan evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT ruihu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT ruihu evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT jinyuyi evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT jinyuyi evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT xinzhong evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT xinzhong evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT jingli evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT jialingsun evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT xiaozhouzhou evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview
AT xiaozhouzhou evidenceconstructionofsilibinincapsulesagainstalcoholicliverdiseasebasedonametaanalysisandsystematicreview